CN110652544A - Pharmaceutical composition for treating rhinitis and preparation method thereof - Google Patents
Pharmaceutical composition for treating rhinitis and preparation method thereof Download PDFInfo
- Publication number
- CN110652544A CN110652544A CN201911144429.7A CN201911144429A CN110652544A CN 110652544 A CN110652544 A CN 110652544A CN 201911144429 A CN201911144429 A CN 201911144429A CN 110652544 A CN110652544 A CN 110652544A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- decoction
- oil
- vegetable oil
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 56
- 206010039083 rhinitis Diseases 0.000 title claims abstract description 44
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 235000015112 vegetable and seed oil Nutrition 0.000 claims abstract description 38
- 239000008158 vegetable oil Substances 0.000 claims abstract description 38
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 36
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims abstract description 36
- 241000402754 Erythranthe moschata Species 0.000 claims abstract description 30
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims abstract description 28
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 claims abstract description 28
- 229940116229 borneol Drugs 0.000 claims abstract description 28
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 claims abstract description 28
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 claims abstract description 28
- 229940041616 menthol Drugs 0.000 claims abstract description 28
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 27
- 241000205585 Aquilegia canadensis Species 0.000 claims abstract description 26
- 240000000691 Houttuynia cordata Species 0.000 claims abstract description 23
- 238000002791 soaking Methods 0.000 claims abstract description 22
- 244000035851 Chrysanthemum leucanthemum Species 0.000 claims abstract description 20
- 235000008495 Chrysanthemum leucanthemum Nutrition 0.000 claims abstract description 20
- 241000628997 Flos Species 0.000 claims abstract description 19
- 241000218378 Magnolia Species 0.000 claims abstract description 17
- 229940107666 astragalus root Drugs 0.000 claims abstract description 14
- 241000112528 Ligusticum striatum Species 0.000 claims abstract description 11
- 235000013719 Houttuynia cordata Nutrition 0.000 claims abstract description 10
- 239000009670 cang er zi wan Substances 0.000 claims abstract description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 4
- 239000009636 Huang Qi Substances 0.000 claims abstract description 4
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 claims abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 4
- 244000067505 Xanthium strumarium Species 0.000 claims abstract 2
- 241000758794 Asarum Species 0.000 claims description 24
- 238000001914 filtration Methods 0.000 claims description 23
- 241000213006 Angelica dahurica Species 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- 241000132012 Atractylodes Species 0.000 claims description 12
- 241000218671 Ephedra Species 0.000 claims description 12
- 241001313857 Bletilla striata Species 0.000 claims description 10
- 240000009138 Curcuma zedoaria Species 0.000 claims description 9
- 235000003405 Curcuma zedoaria Nutrition 0.000 claims description 9
- 241001180876 Saposhnikovia Species 0.000 claims description 9
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 claims description 9
- 235000019509 white turmeric Nutrition 0.000 claims description 9
- 241000931705 Cicada Species 0.000 claims description 8
- 230000010355 oscillation Effects 0.000 claims description 8
- 240000006079 Schisandra chinensis Species 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 239000008159 sesame oil Substances 0.000 claims description 7
- 235000011803 sesame oil Nutrition 0.000 claims description 7
- 240000007641 Spergula rubra Species 0.000 claims description 6
- 239000010677 tea tree oil Substances 0.000 claims description 6
- 229940111630 tea tree oil Drugs 0.000 claims description 6
- 244000111489 Gardenia augusta Species 0.000 claims description 5
- 235000019501 Lemon oil Nutrition 0.000 claims description 5
- 235000019484 Rapeseed oil Nutrition 0.000 claims description 5
- 239000010501 lemon oil Substances 0.000 claims description 5
- 235000008422 Schisandra chinensis Nutrition 0.000 claims description 4
- 239000003921 oil Substances 0.000 claims description 4
- 235000019198 oils Nutrition 0.000 claims description 4
- 239000004006 olive oil Substances 0.000 claims description 4
- 235000008390 olive oil Nutrition 0.000 claims description 4
- 240000007049 Juglans regia Species 0.000 claims description 3
- 235000009496 Juglans regia Nutrition 0.000 claims description 3
- 240000004534 Scutellaria baicalensis Species 0.000 claims description 3
- 235000017089 Scutellaria baicalensis Nutrition 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 235000020234 walnut Nutrition 0.000 claims description 3
- 235000014375 Curcuma Nutrition 0.000 claims description 2
- 244000164480 Curcuma aromatica Species 0.000 claims description 2
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 27
- 208000024891 symptom Diseases 0.000 abstract description 24
- 210000003928 nasal cavity Anatomy 0.000 abstract description 17
- 206010061218 Inflammation Diseases 0.000 abstract description 13
- 230000004054 inflammatory process Effects 0.000 abstract description 13
- 229940079593 drug Drugs 0.000 abstract description 6
- 210000004877 mucosa Anatomy 0.000 abstract description 6
- 210000002850 nasal mucosa Anatomy 0.000 abstract description 6
- 238000004140 cleaning Methods 0.000 abstract description 2
- 210000001989 nasopharynx Anatomy 0.000 abstract description 2
- 230000001681 protective effect Effects 0.000 abstract description 2
- 230000008929 regeneration Effects 0.000 abstract description 2
- 238000011069 regeneration method Methods 0.000 abstract description 2
- 230000008439 repair process Effects 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 60
- 206010039101 Rhinorrhoea Diseases 0.000 description 29
- 206010028748 Nasal obstruction Diseases 0.000 description 18
- 208000010753 nasal discharge Diseases 0.000 description 17
- 230000036407 pain Effects 0.000 description 17
- 230000008961 swelling Effects 0.000 description 17
- 208000002193 Pain Diseases 0.000 description 16
- 208000003251 Pruritus Diseases 0.000 description 15
- 239000002994 raw material Substances 0.000 description 14
- 235000013717 Houttuynia Nutrition 0.000 description 13
- 241001506766 Xanthium Species 0.000 description 13
- 230000006870 function Effects 0.000 description 13
- 239000000463 material Substances 0.000 description 13
- 210000001331 nose Anatomy 0.000 description 13
- 208000036071 Rhinorrhea Diseases 0.000 description 12
- 210000004072 lung Anatomy 0.000 description 10
- 206010019233 Headaches Diseases 0.000 description 9
- 244000153234 Hibiscus abelmoschus Species 0.000 description 9
- 230000007803 itching Effects 0.000 description 9
- 231100000869 headache Toxicity 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 8
- 235000018958 Gardenia augusta Nutrition 0.000 description 7
- 240000001972 Gardenia jasminoides Species 0.000 description 7
- 241000212322 Levisticum officinale Species 0.000 description 7
- 241000191967 Staphylococcus aureus Species 0.000 description 7
- 208000033809 Suppuration Diseases 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 230000000857 drug effect Effects 0.000 description 7
- 230000036039 immunity Effects 0.000 description 7
- 230000001939 inductive effect Effects 0.000 description 7
- 239000001645 levisticum officinale Substances 0.000 description 7
- 238000011084 recovery Methods 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 241000193830 Bacillus <bacterium> Species 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 6
- 230000000844 anti-bacterial effect Effects 0.000 description 6
- 235000006533 astragalus Nutrition 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 244000061520 Angelica archangelica Species 0.000 description 5
- 241001061264 Astragalus Species 0.000 description 5
- 206010007247 Carbuncle Diseases 0.000 description 5
- 235000001287 Guettarda speciosa Nutrition 0.000 description 5
- 206010052437 Nasal discomfort Diseases 0.000 description 5
- 230000007812 deficiency Effects 0.000 description 5
- 230000003467 diminishing effect Effects 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 206010041232 sneezing Diseases 0.000 description 5
- 210000004233 talus Anatomy 0.000 description 5
- QBDCOUHKEVYWLO-UHFFFAOYSA-N Decanoyl acetaldehyde Chemical compound CCCCCCCCCC(=O)CC=O QBDCOUHKEVYWLO-UHFFFAOYSA-N 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 4
- 241000207929 Scutellaria Species 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 208000001848 dysentery Diseases 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000000242 pagocytic effect Effects 0.000 description 4
- 238000005728 strengthening Methods 0.000 description 4
- 230000035900 sweating Effects 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 241000194017 Streptococcus Species 0.000 description 3
- 230000003750 conditioning effect Effects 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- IQVQXVFMNOFTMU-FLIBITNWSA-N (Z)-ligustilide Chemical compound C1CC=CC2=C1C(=C/CCC)/OC2=O IQVQXVFMNOFTMU-FLIBITNWSA-N 0.000 description 2
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 2
- 241001313855 Bletilla Species 0.000 description 2
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 235000006679 Mentha X verticillata Nutrition 0.000 description 2
- 235000002899 Mentha suaveolens Nutrition 0.000 description 2
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 2
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 2
- 201000007100 Pharyngitis Diseases 0.000 description 2
- 102100038567 Properdin Human genes 0.000 description 2
- 108010005642 Properdin Proteins 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 241000191963 Staphylococcus epidermidis Species 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 241000607626 Vibrio cholerae Species 0.000 description 2
- IQVQXVFMNOFTMU-DHZHZOJOSA-N Z-ligustilide Natural products C1CC=CC2=C1C(=C/CCC)\OC2=O IQVQXVFMNOFTMU-DHZHZOJOSA-N 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 229940074393 chlorogenic acid Drugs 0.000 description 2
- 235000001368 chlorogenic acid Nutrition 0.000 description 2
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 2
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 2
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 235000008216 herbs Nutrition 0.000 description 2
- 229960001340 histamine Drugs 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 229940118696 vibrio cholerae Drugs 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- 206010002482 Angiosclerosis Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241001289295 Asarum sieboldii Species 0.000 description 1
- 241000045403 Astragalus propinquus Species 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 206010063659 Aversion Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 235000007516 Chrysanthemum Nutrition 0.000 description 1
- 240000005250 Chrysanthemum indicum Species 0.000 description 1
- SCULJPGYOQQXTK-OLRINKBESA-N Cinobufagin Chemical compound C=1([C@@H]2[C@@]3(C)CC[C@@H]4[C@@]5(C)CC[C@H](O)C[C@H]5CC[C@H]4[C@@]43O[C@@H]4[C@@H]2OC(=O)C)C=CC(=O)OC=1 SCULJPGYOQQXTK-OLRINKBESA-N 0.000 description 1
- SCULJPGYOQQXTK-UHFFFAOYSA-N Cinobufagin Natural products CC(=O)OC1C2OC22C3CCC4CC(O)CCC4(C)C3CCC2(C)C1C=1C=CC(=O)OC=1 SCULJPGYOQQXTK-UHFFFAOYSA-N 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 206010014568 Empyema Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010018286 Gingival pain Diseases 0.000 description 1
- 206010018291 Gingival swelling Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 241000229179 Ledebouriella Species 0.000 description 1
- 241000589902 Leptospira Species 0.000 description 1
- 206010024453 Ligament sprain Diseases 0.000 description 1
- 206010028741 Nasal inflammation Diseases 0.000 description 1
- 241000475481 Nebula Species 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 208000030880 Nose disease Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 241001495449 Robinia pseudoacacia Species 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 241001107098 Rubiaceae Species 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 241000607764 Shigella dysenteriae Species 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 208000037386 Typhoid Diseases 0.000 description 1
- 244000159501 Ximenia caffra Species 0.000 description 1
- 235000001365 Ximenia caffra Nutrition 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002921 anti-spasmodic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- WDIHJSXYQDMJHN-UHFFFAOYSA-L barium chloride Chemical compound [Cl-].[Cl-].[Ba+2] WDIHJSXYQDMJHN-UHFFFAOYSA-L 0.000 description 1
- 229910001626 barium chloride Inorganic materials 0.000 description 1
- 229940045511 barium chloride Drugs 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000009519 contusion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000032669 eclosion Effects 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000017525 heat dissipation Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- JPUKWEQWGBDDQB-DTGCRPNFSA-N kaempferol 3-O-beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=CC(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O JPUKWEQWGBDDQB-DTGCRPNFSA-N 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- -1 lipid peroxide Chemical class 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 210000001034 respiratory center Anatomy 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 230000008786 sensory perception of smell Effects 0.000 description 1
- 239000000779 smoke Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 210000005090 tracheal smooth muscle Anatomy 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 201000008297 typhoid fever Diseases 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/55—Glands not provided for in groups A61K35/22 - A61K35/545, e.g. thyroids, parathyroids or pineal glands
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/236—Ligusticum (licorice-root)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/35—Caprifoliaceae (Honeysuckle family)
- A61K36/355—Lonicera (honeysuckle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/534—Mentha (mint)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/57—Magnoliaceae (Magnolia family)
- A61K36/575—Magnolia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/78—Saururaceae (Lizard's-tail family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/35—Extraction with lipophilic solvents, e.g. Hexane or petrol ether
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Otolaryngology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a pharmaceutical composition for treating rhinitis and a preparation method thereof, and relates to the technical field of medicines. The pharmaceutical composition mainly comprises the following components in parts by weight: 40-60 parts of cocklebur fruit, 40-60 parts of magnolia flower, 13-28 parts of astragalus root, 5-12 parts of ligusticum wallichii, 11-21 parts of honeysuckle, 10-23 parts of houttuynia cordata, 5-12 parts of wild chrysanthemum flower, 3-10 parts of menthol, 3-9 parts of borneol, 1-5 parts of musk and 1000 parts of vegetable oil with 2500 parts of sugar, alcohol and water. The preparation method of the pharmaceutical composition mainly comprises the following steps: soaking fructus Xanthii, flos Magnoliae, radix astragali, rhizoma Ligustici Chuanxiong, flos Lonicerae, herba Houttuyniae and flos Chrysanthemi Indici in vegetable oil for 15-30 hr. The pharmaceutical composition can directly reach the focus of rhinitis, eliminate inflammation, promote repair and regeneration of nasal mucosa, form protective film on the surface of mucosa, recover self-cleaning of nasal cavity, improve self-regulation function of nasopharynx, avoid repeated attack after stopping administration, and treat both symptoms and root causes.
Description
Technical Field
The invention relates to the technical field of medicines, and particularly relates to a pharmaceutical composition for treating rhinitis and a preparation method thereof.
Background
Rhinitis, an inflammatory disease of the nasal cavity, is an inflammation of the nasal mucosa caused by viruses, bacteria, allergens, various physicochemical factors, and certain systemic diseases. The main pathological changes of rhinitis are congestion, swelling, exudation, hyperplasia, atrophy or necrosis of the nasal mucosa. The traditional Chinese medicine considers that the nose leads the orifices and the lung, the nose is the orifice outside the lung, and the fundamental problem of rhinitis is that the nasal cavity is affected by exogenous wind-cold and pathogenic qi, and the nasal cavity has uncomfortable symptoms such as nasal obstruction, rhinorrhea, sneezing, rhinocnesmus, sense of smell reduction, headache, dizziness and the like because the essential qi is insufficient, the viscera are disordered in function, yin and yang are unbalanced, the lung qi is weakened, the immunity of the human body is low, the disease resistance is poor. Therefore, no treatment of nose can be seen, and the intrinsic conditioning must be considered.
Disclosure of Invention
The invention aims to provide a pharmaceutical composition for treating rhinitis, which has better rhinitis treatment effect.
The invention also aims to provide a preparation method of the pharmaceutical composition for treating rhinitis, which is simple and feasible and can ensure that the drug effect of each raw material is dissolved more thoroughly.
The technical problem to be solved by the invention is realized by adopting the following technical scheme.
The invention provides a pharmaceutical composition for treating rhinitis, which mainly comprises the following components in parts by weight:
40-60 parts of cocklebur fruit, 40-60 parts of magnolia flower, 13-28 parts of astragalus root, 5-12 parts of ligusticum wallichii, 11-21 parts of honeysuckle, 10-23 parts of houttuynia cordata, 5-12 parts of wild chrysanthemum flower, 3-10 parts of menthol, 3-9 parts of borneol, 1-5 parts of musk and 1000 parts of vegetable oil with 2500 parts of sugar, alcohol and water.
The invention also provides a preparation method of the pharmaceutical composition, which comprises the following steps: soaking fructus Xanthii, flos Magnoliae, radix astragali, rhizoma Ligustici Chuanxiong, flos Lonicerae, herba Houttuyniae and flos Chrysanthemi Indici in vegetable oil for 15-30 hr.
The pharmaceutical composition for treating rhinitis and the preparation method thereof provided by the embodiment of the invention at least have the following beneficial effects:
the embodiment of the invention provides a pharmaceutical composition for treating rhinitis, which mainly comprises the following components in parts by weight:
40-60 parts of cocklebur fruit, 40-60 parts of magnolia flower, 13-28 parts of astragalus root, 5-12 parts of ligusticum wallichii, 11-21 parts of honeysuckle flower, 10-23 parts of houttuynia cordata, 5-12 parts of wild chrysanthemum flower, 3-10 parts of menthol, 3-9 parts of borneol, 1-5 parts of musk and 1000 parts of vegetable oil. Wherein, the cocklebur fruit is matched with the magnolia flower to disperse wind-cold and ventilate nasal orifices; the menthol, the borneol and the musk are combined to play the efficacies of inducing resuscitation by fragrance, clearing heat, reducing swelling, relieving itching and the like. The pharmaceutical composition can directly reach the focus of rhinitis, eliminate inflammation, eliminate the inflammation, promote the repair and regeneration of nasal mucosa, form a protective film on the surface layer of the mucosa, recover the self-cleaning of nasal cavity, improve the self-regulation function of nasopharynx, avoid repeated attack after stopping administration, and treat both symptoms and root causes. At present, most of the medicines are used for treating the nose through nose, so that the nose is easy to repeat and not easy to improve. The inventor researches and discovers that the functions of 'dispersing and descending' of the lung need to be conditioned while symptoms are treated, only through conditioning of traditional Chinese medicines, the immunity of the organism is established, the damaged nasal mucosa is repaired, and the prevention and radical treatment are facilitated by combining exercise at ordinary times.
The embodiment of the invention also provides a preparation method of the pharmaceutical composition, which mainly comprises the step of soaking the cocklebur fruit, the magnolia flower, the astragalus root, the ligusticum wallichii, the honeysuckle, the cordate houttuynia and the wild chrysanthemum in vegetable oil for 15-30 hours. The method is simple and easy to implement, and the medicinal materials are fully soaked in the vegetable oil, so that the vegetable oil can fully absorb the effective components in the raw materials of the medicinal materials, and the medicinal composition has quicker response and more stable curative effect.
Detailed Description
In order to make the objects, technical solutions and advantages of the embodiments of the present invention clearer, the technical solutions in the embodiments of the present invention will be clearly and completely described below. The examples, in which specific conditions are not specified, were conducted under conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products available commercially.
It should be noted that the embodiments and features of the embodiments in the present application may be combined with each other without conflict. The present invention will be described in detail below with reference to specific examples.
The embodiment of the invention provides a pharmaceutical composition for treating rhinitis, which mainly comprises the following components in parts by weight:
40-60 parts of cocklebur fruit, 40-60 parts of magnolia flower, 13-28 parts of astragalus root, 5-12 parts of ligusticum wallichii, 11-21 parts of honeysuckle flower, 10-23 parts of houttuynia cordata, 5-12 parts of wild chrysanthemum flower, 3-10 parts of menthol, 3-9 parts of borneol, 1-5 parts of musk and 1000 parts of vegetable oil. Further, the pharmaceutical composition can also comprise the following components in parts by weight: 30-50 parts of angelica dahurica, 10-22 parts of bighead atractylodes rhizome, 10-22 parts of divaricate saposhnikovia root and 6-13 parts of curcuma zedoary. E Zhu is pungent, bitter and warm in nature, entering liver and spleen meridians. Has effects in removing blood stasis, promoting qi circulation, removing food stagnation, and relieving pain. The zedoary has antibacterial effect, and the zedoary volatile oil can inhibit the growth of Staphylococcus aureus, hemolytic streptococcus, Escherichia coli, Salmonella typhi, Vibrio cholerae, etc. in test tube. In the formula, the astragalus and the white atractylodes rhizome are matched with the honeysuckle, the heartleaf houttuynia herb and the wild chrysanthemum flower, and the Chinese medicinal composition has the effects of tonifying lung qi, strengthening defensive qi, relieving exterior syndrome, clearing away heat and toxic materials, eliminating carbuncle and expelling pus; fructus Xanthii is combined with flos Magnoliae to dispel wind-cold and dredge nasal orifice; the angelica dahurica is matched with the divaricate saposhnikovia root to strengthen the function of dispersing wind-cold and effectively relieve pain caused by rhinitis, and the zedoary assists to strengthen and relieve the symptoms of pain, mucosa swelling, nasal itching and the like; the menthol, the borneol and the musk are combined to play the efficacies of inducing resuscitation by fragrance, clearing heat, reducing swelling, relieving itching and the like. The menthol cream is a cream prepared from traditional Chinese medicine mint, and has the functions of diminishing inflammation, resisting allergy and preserving moisture. Borneolum has effects of inducing resuscitation, refreshing mind, clearing heat, relieving swelling, and relieving itching, and can be used for treating eczema, chronic nasal inflammation, and skin pruritus. Moschus has effects in inducing resuscitation, removing dirt, dredging collaterals, and removing blood stasis. Has good effect on people with obstruction of orifices and channels. Modern researches show that the musk extract musk tincture diluent can inhibit escherichia coli and staphylococcus aureus in a test tube.
The fructus xanthil has the following effects:
(1) dispersing wind-cold: the fructus Xanthii is pungent and warm in property and disperses, can not only disperse wind-cold but also dredge nasal orifices and relieve pain, and can be used for treating discomfort symptoms such as wind-cold, aversion to cold, fever, headache and body pain, nasal obstruction, watery nasal discharge and the like.
(2) Relieving stuffy nose: fructus Xanthii is mild and comfortable, pungent in taste and capable of dispelling wind, bitter and eliminating dampness, good for dredging nasal orifices to improve nasal obstruction, relieve forehead and nose swelling pain, and can be used for treating nasal obstruction, watery nasal discharge, smellless odor and headache caused by nasal diseases such as allergic rhinitis and nasosinusitis.
(3) Bacteriostasis and inflammation diminishing: the fructus Xanthii has certain inhibitory effect on Staphylococcus aureus, Streptococcus B, Diplococcus pneumoniae, etc., and can resist fungi.
The magnolia flower has the following effects:
dispelling wind-cold, dredging nasal orifice: flos Magnoliae has the effects of dispelling wind-cold and relieving stuffy nose, and can be used for treating wind-cold headache, nasal obstruction, watery nasal discharge, etc., and is a special medicine for treating rhinopathy. The inventor researches and discovers that the magnolia flower has the functions of astringing and protecting the nasal mucosa, reducing secretion, expanding local microvessels, improving blood circulation, promoting the absorption of nasal secretion and the resolution of inflammation, has the functions of resisting inflammation, easing pain and resisting allergy in local application, and can be clinically used for various rhinitis.
The astragalus adopts honey processed astragalus: has effects of invigorating qi and consolidating superficial resistance, and can be used for treating lung qi deficiency, collapse of middle-warmer energy, and spontaneous perspiration due to exterior deficiency. The inventor researches and discovers that the astragalus membranaceus processed with honey also has the effects of enhancing the immune function, enhancing the hypoxia tolerance and stress resistance of an organism, promoting the metabolism of the organism, improving the lung function, resisting bacteria, inhibiting viruses and the like.
The angelica dahurica has the following effects:
(1) dispersing wind-cold: radix Angelicae Dahuricae, being pungent and warm in property and dredging, has mild effects of dispelling pathogenic wind, relieving exterior syndrome and dispelling cold, and has good analgesic effect, so it can be used for treating wind cold, headache and body pain, nasal obstruction and watery nasal discharge.
(2) And (3) pain relieving: radix Angelicae Dahuricae, with pungent flavor and pungent flavor, is good at relieving pain, and is mainly used in the stomach meridian of foot yangming, so radix Angelicae Dahuricae is often used for treating forehead headache and gingival swelling and pain of yangming meridian, and can be used for treating yangming headache, brow bone headache, etc.
(3) Swelling reduction: the radix angelicae dahuricae is pungent and has the effects of dispelling heat and dredging, relieving swelling and expelling pus, and can be used for treating initial sores and ulcers and red swelling and pain, and has the effects of relieving swelling and pain; if abscess has already formed, it can be used with qi-tonifying and blood-enriching herbs to achieve the effect of detoxification and pus discharge.
(4) Relieving itching: the angelica dahurica can dispel wind and dry dampness, and the traditional Chinese medicine considers that skin itch is mainly caused by wind evil and dampness evil, so the angelica dahurica can also be used for treating symptoms such as skin mucosa itch and the like.
The white atractylodes rhizome has the following effects:
(1) consolidating superficial resistance and arresting sweating: bighead atractylodes rhizome, rhizoma Atractylodis Macrocephalae, with the actions of replenishing qi to invigorate the spleen, consolidating superficial resistance and arresting sweating, is similar to Huang Qi, but weak in strength and weak in strength, and is commonly used for treating patients with spleen-qi deficiency and sweating. For spontaneous sweating due to exterior deficiency and susceptibility to wind-cold due to deficiency of spleen-lung qi, defensive qi is not firm, it is combined with herbs of tonifying spleen-lung, dispelling wind-evil and dispersing pathogen such as Huang Qi and Fang Feng.
(2) Antioxidation: the rhizoma atractylodis macrocephalae has an antioxidation effect, can effectively inhibit lipid peroxidation and reduce the content of tissue lipid peroxide, thereby avoiding the damage of harmful substances to the structure and the function of tissue cells.
(3) Improving immunity: atractylodis rhizoma can increase phagocytic function of reticuloendothelial system, and improve lymphocyte and immunoglobulin.
The rhizoma ligustici wallichii has the following effects:
(1) and (3) promoting respiration: when the volatile oil contained in the ligusticum wallichii is large in dosage, the ligusticum wallichii can excite the brain-extending respiratory center, the blood vessel movement center and the spinal cord reflex center.
(2) Antibacterial and anti-inflammatory effects: the ligusticum wallichii has obvious inhibition effect on various gram-negative intestinal bacteria, so the ligusticum wallichii has inhibition effect on large intestine, dysentery, deformation, pyocyanea, typhoid, paratyphoid bacillus, vibrio cholerae and the like.
Modern research shows that: ligustilide contained in rhizoma Ligustici Chuanxiong has antispasmodic effect on smooth muscle, and can be used for relieving spasm and contraction of tracheal smooth muscle caused by acetylcholine, histamine and barium chloride, mainly because ligustilide can relieve asthmatic reaction of histamine and acetylcholine.
The divaricate saposhnikovia root has the following effects:
(1) and (3) antibiosis: the decoction of radix Saposhnikoviae has effect in inhibiting various bacteria such as Bacillus dysenteriae. The fresh divaricate saposhnikovia root juice has a certain antibacterial effect on pseudomonas aeruginosa and staphylococcus aureus, and the decoction has different degrees of inhibitory effects on dysentery bacillus, hemolytic streptococcus and the like.
(2) Relieving itching: ledebouriella root, radix Saposhnikoviae, with pungent and warm natured drugs, can dispel wind and relieve itching.
The honeysuckle flower (namely honeysuckle flower) has the following effects:
(1) detumescence and detoxification: honeysuckle flower, flos Lonicerae, sweet and cold in flavor, can clear away heat and toxic materials.
(2) Wind heat dissipation: honeysuckle flower is sweet and cold, fragrant and capable of dispelling lung channel heat evil and expelling pathogenic heat from the body, and can be used for treating diseases such as exogenous wind-heat or fever at the beginning of warm disease, pharyngalgia and thirst.
(3) The antibacterial effect is as follows: the honeysuckle has broad-spectrum antibacterial effect, has strong inhibition effect on pathogenic bacteria such as staphylococcus aureus, dysentery bacillus and the like, and has inhibition effect on various pathogenic microorganisms such as leptospira, influenza virus, pathogenic mould and the like.
(4) And (3) enhancing immunity: the flos Lonicerae has effects of promoting phagocytic ability of leukocyte, and enhancing immunity. The biological activity of chlorogenic acid contained in the honeysuckle can promote the metabolism of the human body and regulate the functions of the human body after entering the human body, thereby helping to improve the immunity of the human body.
(5) Anti-inflammatory action: the effective components in flos Lonicerae have antiinflammatory and antipyretic effects, and can effectively promote release of adrenocortical hormone, and inhibit various inflammation and swelling and pain.
The inventor researches and discovers that: chlorogenic acid in the honeysuckle has a certain antiviral effect, and trifolioside in the honeysuckle has strong activity of resisting respiratory syncytial virus. The ethanol extract in the honeysuckle has obvious antiallergic activity.
The houttuynia cordata has the following effects:
(1) diminishing inflammation: the cordate houttuynia is a natural and safe antibiotic, is beneficial to clearing heat, diminishing inflammation and resisting viruses, has the medicine property of reaching the upper, middle and lower triple energizers of a human body, and has excellent curative effects on wind-heat type common cold, pharyngitis, pneumonia and other inflammations caused by various bacterial viruses, urinary system infection, reproductive system infection and skin inflammation.
(2) Bacteriostasis: the houttuynin in the houttuynia cordata has certain inhibition effect on staphylococcus aureus, staphylococcus albus, dysentery bacillus, pseudomonas aeruginosa, attenuated bacillus, side escherichia coli and gram-positive bacillus, and has strong inhibition effect on staphylococcus.
(3) Carbuncle eliminating and pus discharging: the heartleaf houttuynia herb is pungent and cold, can eliminate carbuncle and discharge pus, can be used for treating heat-toxin sores and ulcers by external application, and can also be used for treating phlegm-heat obstructing the lung, chest pain, cough, empyema, bloody odor and other diseases by oral administration.
(4) And (3) enhancing immunity: the houttuynia cordata can enhance the phagocytic capacity of white blood cells and improve serum properdin, and when the houttuynia cordata is used for treating tracheitis, the synthesized houttuynin can obviously improve the phagocytic capacity of white blood cells of a patient on staphylococcus albus and obviously improve the serum properdin.
The wild chrysanthemum has the following effects:
antibacterial and anti-inflammatory effects: the wild chrysanthemum contains the Chrysanthemum alcohol which has killing effect on a plurality of bacteria and strong effect, especially has the strongest killing effect on Escherichia coli and Staphylococcus aureus, and can effectively kill bacteria when the concentration reaches 15 mg/ml. Therefore, the wild chrysanthemum flower has good effects of sterilizing, diminishing inflammation and reducing swelling when being drunk or being smeared at edema caused by infection by being soaked in water.
The pharmaceutical composition can also be further added with the following raw materials in parts by weight:
10-19 parts of bletilla striata, 4-12 parts of ephedra, 5-15 parts of starwort root, 7-16 parts of cicada shell and 5-12 parts of asarum. Periostracum Cicadae is the shell of cicada family insect black locust which falls off when the larva eclosion takes place, and has the effects of dissipating heat and removing heat, relieving sore throat, promoting eruption, removing nebula, relieving spasm and the like. The asarum is also called asarum sieboldii and asarum schreberi, has the effects of dispelling wind, dispelling cold, promoting diuresis and inducing resuscitation, and also has the effects of treating wind-cold headache, nasosinusitis, toothache, phlegm-fluid cough, rheumatic arthralgia and the like. In the formula, the astragalus and the bletilla are matched with honeysuckle, heartleaf houttuynia herb and wild chrysanthemum, the formula has the effects of tonifying lung qi, strengthening the defense and relieving exterior syndrome, clearing away heat and toxic materials, eliminating carbuncle and expelling pus; fructus Xanthii is combined with flos Magnoliae to dispel wind-cold and dredge nasal orifice; the ephedra stem is matched with the starwort root to strengthen the function of dispersing wind-cold and effectively relieve the symptoms of pain, mucosa swelling, nasal itching and the like caused by rhinitis; the asarum and the cicada slough are matched, and the asarum and the cicada slough are used for dispelling cold and removing heat in a synergistic manner, so that a more appropriate environment is provided for treating rhinitis in a patient body, and each medicinal component can reach a focus more accurately when acting; the menthol, the borneol and the musk are combined to play the efficacies of inducing resuscitation by fragrance, clearing heat, reducing swelling, relieving itching and the like.
The pharmaceutical composition can also adopt the following formula in parts by weight:
40-60 parts of cocklebur fruit, 40-60 parts of magnolia flower, 13-28 parts of astragalus root, 5-12 parts of ligusticum wallichii, 11-21 parts of honeysuckle, 10-23 parts of houttuynia cordata, 5-12 parts of wild chrysanthemum flower, 3-10 parts of menthol, 3-9 parts of borneol, 1-5 parts of musk, 1000 parts of vegetable oil, 2500 parts of mangnolia officinalis, 5-12 parts of bletilla striata, 4-13 parts of asarum, 3-10 parts of ephedra, 10-20 parts of scutellaria baicalensis, 2-7 parts of gardenia, 1-5 parts of dark plum, 3-10 parts of schisandra chinensis and 8-16 parts of rhizoma atractylodis. Baikal skullcap root has the efficacy of clearing heat and drying dampness, and is mainly used for treating warm diseases. Cape jasmine has the alias: gardenia jasminoides Ellis, Gardenia jasminoides Ellis and Cinobufagin are fruits of Gardenia jasminoides Ellis of Rubiaceae. The fruit of gardenia is a traditional Chinese medicine, belongs to the first batch of medical and edible dual-purpose resources issued by the Ministry of health, and has the functions of protecting liver, benefiting gallbladder, reducing blood pressure, calming, stopping bleeding, reducing swelling and the like. Is used for treating icteric hepatitis, sprain, contusion, hypertension, diabetes and other diseases in traditional Chinese medicine clinic. The mume fructus is named as sour plum, yellow boy, Hehan plum, and dry branch plum, and is prepared from nearly mature fruit of plum of Rosaceae deciduous tree by smoking with smoke. The plum contains tea acid which can promote intestinal peristalsis, so people with constipation should eat the plum. The plum contains various organic acids, and has the effect of improving liver function, so it is suitable for patients with liver diseases. The pruric acid in mume fructus has effects of softening blood vessel, delaying angiosclerosis, and resisting aging. The schisandra chinensis can tonify and strengthen the body, has high medicinal value and has the effect of strengthening the body. Rhizoma Atractylodis rhizome, as a spleen-activating herb, has the actions of drying dampness, resolving turbidity and alleviating pain.
In the formula, the astragalus and the bletilla are matched with honeysuckle, heartleaf houttuynia herb and wild chrysanthemum, the formula has the effects of tonifying lung qi, strengthening the defense and relieving exterior syndrome, clearing away heat and toxic materials, eliminating carbuncle and expelling pus; fructus Xanthii is combined with flos Magnoliae to dispel wind-cold and dredge nasal orifice; the ephedra stem is matched with the baical skullcap root to strengthen the function of dispersing wind-cold and effectively relieve the symptoms of pain, mucosa swelling, nasal itching and the like caused by rhinitis; the asarum is matched with the schisandra and the gardenia, and the asarum and the gardenia are used for dispelling cold and removing heat in a synergistic manner, so that a more appropriate environment is provided for treating rhinitis in a patient body, and each medicinal component can reach a focus more accurately when acting; rhizoma atractylodis and rhizoma ligustici wallichii can cooperate to play a guiding role on active ingredients of other medicines, so that the medicines are absorbed more thoroughly; the mint cream, the borneol, the musk and the dark plum are combined to play the effects of inducing resuscitation with aromatics, clearing heat, reducing swelling, relieving itching and the like.
In the embodiment of the invention, the vegetable oil can be one or more of sesame oil, tea tree oil, olive oil, rapeseed oil, walnut kernel oil and lemon oil. The use of the vegetable oil can facilitate the preparation of the medicinal composition into oily medicaments, and ensure that the raw materials of various medicaments are fused more thoroughly, the medicinal effect is more obvious and the use is more convenient. The sesame oil is used as solvent, contains substances such as linoleic acid, vitamins, trace elements and the like, and has the effects of detoxifying, promoting the growth of muscles and improving the metabolism of cells in a human body.
The embodiment of the invention also provides a preparation method of the pharmaceutical composition for treating rhinitis, which mainly comprises the following steps:
soaking fructus Xanthii, flos Magnoliae, radix astragali, rhizoma Ligustici Chuanxiong, flos Lonicerae, herba Houttuyniae, flos Chrysanthemi Indici, radix Angelicae Dahuricae, Atractylodis rhizoma, radix Saposhnikoviae and Curcumae rhizoma in vegetable oil for 15-30 hr. The soaking process can make the vegetable oil more fully absorb the drug effect of each raw material, so that the drug effect can be more directly acted on the body of a patient. After soaking, decocting the obtained mixture with slow fire until the radix angelicae turns from white to yellow, and approximately goes through 0.5-1And stopping decocting within a short time. The slow fire decoction can avoid the phenomenon that the decoction progress is difficult to control, the phenomenon of excessive decoction and even paste decoction easily occur, and the drug effect is influenced. According to repeated experimental research of the inventor, whether decocting is sufficient or not can be well controlled according to the color change of the angelica dahurica in the decocting process, and the obtained decoction is indicated according to the color change of the angelica dahurica, so that the effective components in the decoction are most abundant, the loss is least, and the drug effect is more remarkable. After decocting, filtering the obtained decoction, wherein the obtained decoction can be filtered by a sieve with 50-100 meshes. After the filtered decoction is cooled to below 50 ℃, the borneol, the menthol and the musk are added into the decoction to avoid the volatilization of the borneol, the menthol and the musk caused by overhigh temperature, thereby losing the drug effect. Finally, the filtered decoction liquid can be subjected to ultrasonic oscillation treatment for 30-50 seconds, so that the borneol, the menthol and the musk are mixed more fully in the oil liquid, and the drug effect is more uniform.
The features and properties of the present invention are described in further detail below with reference to examples.
Example 1
The embodiment provides a pharmaceutical composition for treating rhinitis, which is prepared from the following main raw materials:
40g of cocklebur fruit, 40g of biond magnolia flower, 13g of astragalus root, 5g of szechuan lovage rhizome, 11g of honeysuckle flower, 10g of heartleaf houttuynia herb, 5g of wild chrysanthemum flower, 3g of menthol, 3g of borneol, 1g of musk, 1000g of vegetable oil, 30g of angelica dahurica, 10g of largehead atractylodes rhizome, 10g of divaricate saposhnikovia root and 6g of zedoary. Wherein the vegetable oil is tea tree oil.
The preparation method of the pharmaceutical composition for treating rhinitis comprises the following steps:
soaking all the materials except Borneolum Syntheticum, Mentholum, and Moschus in vegetable oil for 15 hr. After soaking, the soaked mixture is decocted by slow fire for 0.5 hour (the angelica dahurica turns from white to yellow). After the decoction is finished, filtering the obtained decoction, and filtering through a 50-mesh sieve during the filtration. After the decoction is cooled to 50 ℃, adding borneol, menthol and musk into the decoction, and then carrying out ultrasonic oscillation treatment for 30 seconds. And finally bottling for later use.
Example 2
The embodiment provides a pharmaceutical composition for treating rhinitis, which is prepared from the following main raw materials:
60g of cocklebur fruit, 60g of biond magnolia flower, 28g of astragalus root, 12g of szechuan lovage rhizome, 21g of honeysuckle flower, 23g of heartleaf houttuynia herb, 12g of wild chrysanthemum flower, 10g of menthol, 9g of borneol, 5g of musk, 2500g of vegetable oil, 50g of angelica dahurica, 22g of largehead atractylodes rhizome, 22g of divaricate saposhnikovia root, 13g of zedoary, 19g of bletilla striata, 12g of ephedra herb, 15g of starwort root, 16g of cicada shell and 12 g. Wherein the vegetable oil is olive oil.
The preparation method of the pharmaceutical composition for treating rhinitis comprises the following steps:
soaking all the materials except Borneolum Syntheticum, Mentholum, and Moschus in vegetable oil for 30 hr. After soaking, the soaked mixture is decocted by slow fire for 1 hour (the angelica dahurica turns from white to yellow). After the decoction is finished, filtering the obtained decoction, and filtering through a 70-mesh sieve during filtering. After the decoction is cooled to 49 ℃, adding borneol, menthol and musk into the decoction, and then carrying out ultrasonic oscillation treatment for 40 seconds. And finally bottling for later use.
Example 3
The embodiment provides a pharmaceutical composition for treating rhinitis, which is prepared from the following main raw materials:
50g of cocklebur fruit, 50g of biond magnolia flower, 20g of astragalus root, 10g of szechuan lovage rhizome, 15g of honeysuckle flower, 15g of heartleaf houttuynia herb, 10g of wild chrysanthemum flower, 6g of menthol, 6g of borneol, 3g of musk, 1840g of vegetable oil, 40g of dahurian angelica root, 15g of largehead atractylodes rhizome, 15g of divaricate saposhnikovia root, 10g of zedoary, 10g of bletilla striata, 4g of ephedra herb, 5g of starwort root, 7g of cicada shell and 5. Wherein the vegetable oil is sesame oil.
The preparation method of the pharmaceutical composition for treating rhinitis comprises the following steps:
soaking all the materials except Borneolum Syntheticum, Mentholum, and Moschus in vegetable oil for 24 hr. After soaking, decocting the soaked mixture by slow fire, and decocting0.8Hour (degree of change from white to yellow of angelica root). After the decoction is finished, filtering the obtained decoction, and filtering through a 100-mesh sieve during filtering. When the decoction is cooled to 48 ℃, adding borneol, menthol and musk into the decoction. And finally bottling for later use.
Example 4
The embodiment provides a pharmaceutical composition for treating rhinitis, which is prepared from the following main raw materials:
45g of cocklebur fruit, 45g of biond magnolia flower, 20g of astragalus root, 10g of szechuan lovage rhizome, 18g of honeysuckle flower, 12g of heartleaf houttuynia herb, 8g of wild chrysanthemum flower, 6g of menthol, 5g of borneol, 3g of musk, 1100g of vegetable oil, 35g of angelica dahurica, 18g of largehead atractylodes rhizome, 18g of divaricate saposhnikovia root, 9g of zedoary, 15g of bletilla striata, 8g of ephedra herb, 10g of starwort root, 12g of cicada shell and 8 g. Wherein the vegetable oil is rapeseed oil and walnut kernel oil with the mass ratio of 1: 1.
The preparation method of the pharmaceutical composition for treating rhinitis comprises the following steps:
soaking all the materials except Borneolum Syntheticum, Mentholum, and Moschus in vegetable oil for 20 hr. After soaking, decocting the soaked mixture by slow fire, and decocting0.6Hour (degree of change from white to yellow of angelica root). After the decoction is finished, filtering the obtained decoction, and filtering through a 80-mesh sieve during filtering. After the decoction is cooled to 45 ℃, adding borneol, menthol and musk into the decoction, and then carrying out ultrasonic oscillation treatment for 45 seconds. And finally bottling for later use.
Example 5
The embodiment provides a pharmaceutical composition for treating rhinitis, which is prepared from the following main raw materials:
55g of cocklebur fruit, 48g of biond magnolia flower, 25g of astragalus root, 7g of szechuan lovage rhizome, 19g of honeysuckle flower, 16g of heartleaf houttuynia herb, 6g of wild chrysanthemum flower, 7g of menthol, 4g of borneol, 2g of musk, 1200g of vegetable oil, 5g of bletilla striata, 4g of asarum, 3g of ephedra herb, 10g of baical skullcap root, 2g of cape jasmine fruit, 1g of dark plum fruit, 3g of Chinese magnoliavine fruit and 8g of swordlike atractylodes rhizome. Wherein the vegetable oil is lemon oil, sesame oil and tea tree oil in a mass ratio of 1:1: 2.
The preparation method of the pharmaceutical composition for treating rhinitis comprises the following steps:
soaking all the materials except Borneolum Syntheticum, Mentholum, and Moschus in vegetable oil for 25 hr. After soaking, decocting the soaked mixture by slow fire, and decocting0.7Hour (degree of change from white to yellow of angelica root). After the decoction is finished, filtering the obtained decoction, and filtering through a 90-mesh sieve during the filtration. After the decoction is cooled to 30 ℃, adding borneol, menthol and musk into the decoction, and then carrying out ultrasonic oscillation treatment for 40 seconds. And finally bottling for later use.
Example 6
The embodiment provides a pharmaceutical composition for treating rhinitis, which is prepared from the following main raw materials:
58g of cocklebur fruit, 42g of biond magnolia flower, 17g of astragalus root, 11g of szechuan lovage rhizome, 20g of honeysuckle flower, 13g of heartleaf houttuynia herb, 11g of wild chrysanthemum flower, 9g of menthol, 8g of borneol, 4g of musk, 1500g of vegetable oil, 12g of bletilla striata, 13g of asarum, 10g of ephedra herb, 20g of baical skullcap root, 7g of cape jasmine fruit, 5g of dark plum fruit, 10g of Chinese magnoliavine fruit and 16g of swordlike atractylodes rhizome. Wherein the vegetable oil is prepared from the following raw materials in a mass ratio of 1:1: 2: 2 lemon oil, rapeseed oil, sesame oil and tea tree oil.
The preparation method of the pharmaceutical composition for treating rhinitis comprises the following steps:
soaking all the materials except Borneolum Syntheticum, Mentholum, and Moschus in vegetable oil for 24 hr. After soaking, decocting the soaked mixture by slow fire, and decocting0.9Hour (degree of change from white to yellow of angelica root). After the decoction is finished, filtering the obtained decoction, and filtering through a 100-mesh sieve during filtering. Cooling the decoction to 50 deg.C, adding Borneolum Syntheticum, Mentholum and Moschus into the decoctionUltrasonic oscillation is adopted for 30 seconds. And finally bottling for later use.
Example 7
The embodiment provides a pharmaceutical composition for treating rhinitis, which is prepared from the following main raw materials:
43g of cocklebur fruit, 58g of biond magnolia flower, 21g of astragalus root, 9g of szechuan lovage rhizome, 18g of honeysuckle flower, 18g of heartleaf houttuynia herb, 8g of wild chrysanthemum flower, 7g of menthol, 5g of borneol, 3g of musk, 2300g of vegetable oil, 9g of bletilla striata, 10g of asarum, 7g of ephedra herb, 15g of baical skullcap root, 5g of cape jasmine fruit, 3g of dark plum fruit, 7g of Chinese magnoliavine fruit and 11g of swordlike atractylodes rhizome. Wherein the vegetable oil is prepared from the following raw materials in a mass ratio of 1:1: 2: 2: 1.5 of lemon oil, rapeseed oil, olive oil, sesame oil and tea tree oil.
The preparation method of the pharmaceutical composition for treating rhinitis comprises the following steps:
soaking all the materials except Borneolum Syntheticum, Mentholum, and Moschus in vegetable oil for 30 hr. After soaking, decocting the soaked mixture by slow fire, and decocting0.5Hour (degree of change from white to yellow of angelica root). After the decoction is finished, filtering the obtained decoction, and filtering through a 50-mesh sieve during the filtration. After the decoction is cooled to 35 ℃, adding borneol, menthol and musk into the decoction, and then carrying out ultrasonic oscillation treatment for 35 seconds. And finally bottling for later use.
Treatment of case 1
The patients: shen in a certain sex: age of the male: age 28.
Occupation: a doctor; the time of the visit: 6 and 15 months in 2018.
Home address: ningxia Wuzhong; and (4) contacting the telephone: 1537957****.
Clinical symptoms: nasal obstruction, watery nasal discharge, sneezing; the administration time is as follows: for 20 days (using the pharmaceutical composition provided in example 1).
Tracking the curative effect: the medicine is taken after 6 months, and the nasal cavity is unobstructed and the nasal discharge is normal after 7 months.
Treatment of case 2
The patients: topology by gender: age of the male: age 29.
Occupation: a teacher; the time of the visit: year 2018, 6 and 20.
Home address: ningxia Zhongwei City; and (4) contacting the telephone: 1512180****.
Clinical symptoms: nasal obstruction, runny nose, sneezing; the administration time is as follows: 28 days (using the pharmaceutical composition provided in example 2).
Tracking the curative effect: after 6 months of administration, the nasal cavity is unobstructed and the nasal discharge is normal after 7 months of recovery.
Treatment of case 3
The patients: gender by week: age of the woman: age 38.
Occupation: a staff member; the time of the visit: 7 and 3 months in 2018.
Home address: ningxia Wuzhong; and (4) contacting the telephone: 1361957****
Clinical symptoms: nasal obstruction, runny nose, sneezing, itchy nose; the administration time is as follows: for 26 days (using the pharmaceutical composition provided in example 3).
Tracking the curative effect: the medicine is taken in 7 months, and the nasal cavity is healed in 8 months, the nasal discharge is normal, and the symptoms of nasal itching are eliminated due to sneezing occasionally.
Treatment of case 4
The patients: threo gender: age of the male: age 39.
Occupation: a driver; the time of the visit: 7 and 9 in 2018.
Home address: ningxia Yinchuan city; and (4) contacting the telephone: 1361951****.
Clinical symptoms: nasal obstruction, runny nose, itchy nose; the administration time is as follows: for 24 days (using the pharmaceutical composition provided in example 4).
Tracking the curative effect: the medicine is taken for 7 months, the nasal cavity is smooth, the nasal discharge is normal, and the nose itching symptom is eliminated after 8 months of healing.
Treatment of case 5
The patients: xu x sex: age of the male: age 27.
Occupation: a staff member; the time of the visit: 26/7/2018.
Home address: ningxia Yinchuan city; and (4) contacting the telephone: 1539503****.
Clinical symptoms: nasal obstruction, runny nose; the administration time is as follows: for 19 days (using the pharmaceutical composition provided in example 5).
Tracking the curative effect: the medicine is taken in 7 months, and the nasal cavity is unobstructed and the nasal discharge is normal after 8 months of healing.
Treatment of case 6
The patients: kang x sex: age of the male: age 27.
Occupation: a staff member; the time of the visit: 8 and 2 months in 2018.
Home address: ningxia Yinchuan city; and (4) contacting the telephone: 1399503****.
Clinical symptoms: nasal obstruction, runny nose; the administration time is as follows: for 21 days (using the pharmaceutical composition provided in example 6).
Tracking the curative effect: the medicine is taken in 8 months, and the nasal cavity is unobstructed and the nasal discharge is normal after 9 months of recovery.
Treatment of case 7
The patients: week x sex: age of the male: age 40.
Occupation: a staff member; the time of the visit: 8 and 5 months in 2018.
Home address: ningxia Yinchuan city; and (4) contacting the telephone: 1775231****.
Clinical symptoms: nasal obstruction, runny nose; the administration time is as follows: for 26 days (using the pharmaceutical composition provided in example 7).
Tracking the curative effect: the medicine is taken in 8 months, and the nasal cavity is unobstructed and the nasal discharge is normal after 9 months of recovery.
Treatment of case 8
The patients: gender open: age of the woman: age 40.
Occupation: a staff member; the time of the visit: 8 and 12 months in 2018.
Home address: ningxia Yinchuan city; and (4) contacting the telephone: 1364950****.
Clinical symptoms: nasal obstruction, runny nose, itchy nose; the administration time is as follows: for 21 days (using the pharmaceutical composition provided in example 3).
Tracking the curative effect: the medicine is taken for 8 months, the nasal cavity is smooth, the nasal discharge is normal, and the nasal itching symptom is eliminated after 9 months of healing.
Treatment of example 9
The patients: liu · gender: age of the woman: age 28.
Occupation: a staff member; the time of the visit: 8 and 15 days 2018.
Home address: ningxia Wuzhong; and (4) contacting the telephone: 1351950****.
Clinical symptoms: nasal obstruction, runny nose; the administration time is as follows: for 23 days (using the pharmaceutical composition provided in example 3).
Tracking the curative effect: the medicine is taken in 8 months, and the nasal cavity is unobstructed and the nasal discharge is normal after 9 months of recovery.
Treatment of case 10
The patients: stone gender: age of the woman: age 40.
Occupation: staff; the time of the visit: 8 and 17 months in 2018.
Home address: ningxia Yinchuan city; and (4) contacting the telephone: 1362951****.
Clinical symptoms: nasal obstruction, runny nose; the administration time is as follows: for 27 days (using the pharmaceutical composition provided in example 3).
Tracking the curative effect: the medicine is taken in 8 months, and the nasal cavity is unobstructed and the nasal discharge is normal after 9 months of recovery.
Treatment of case 11
The patients: wang x sex: age of the woman: age 45.
Occupation: a staff member; the time of the visit: 8 and 21 months in 2018.
Home address: ningxia Yinchuan city; and (4) contacting the telephone: 1829510****.
Clinical symptoms: nasal obstruction, runny nose; the administration time is as follows: for 20 days (using the pharmaceutical composition provided in example 3).
Tracking the curative effect: the medicine is taken in 8 months, and the nasal cavity is unobstructed and the nasal discharge is normal after 9 months of recovery.
Treatment of case 12
The patients: adult gender: age of the male: age 27.
Occupation: a staff member; the time of the visit: 8 and 25 months in 2018.
Home address: ningxia Yinchuan city contact telephone: 1530958****.
Clinical symptoms: nasal obstruction, runny nose; the administration time is as follows: for 24 days (using the pharmaceutical composition provided in example 3).
Tracking the curative effect: the medicine is taken in 8 months, and the nasal cavity is unobstructed and the nasal discharge is normal after 9 months of recovery.
In conclusion, the pharmaceutical composition for treating rhinitis provided by the embodiment of the invention is oily, convenient to use, remarkable in curative effect and quick in effect, and has a better radical treatment condition through traditional Chinese medicine conditioning.
The embodiments described above are some, but not all embodiments of the invention. The detailed description of the embodiments of the present invention is not intended to limit the scope of the invention as claimed, but is merely representative of selected embodiments of the invention. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.
Claims (10)
1. The pharmaceutical composition for treating rhinitis is characterized by comprising the following components in parts by weight:
40-60 parts of cocklebur fruit, 40-60 parts of magnolia flower, 13-28 parts of astragalus root, 5-12 parts of ligusticum wallichii, 11-21 parts of honeysuckle, 10-23 parts of houttuynia cordata, 5-12 parts of wild chrysanthemum flower, 3-10 parts of menthol, 3-9 parts of borneol, 1-5 parts of musk and 1000 parts of vegetable oil with 2500 parts of sugar, alcohol and water.
2. The pharmaceutical composition for treating rhinitis according to claim 1, wherein the pharmaceutical composition further comprises the following components in parts by weight: 30-50 parts of angelica dahurica, 10-22 parts of bighead atractylodes rhizome, 10-22 parts of divaricate saposhnikovia root and 6-13 parts of curcuma zedoary.
3. The pharmaceutical composition for treating rhinitis according to claim 2, wherein the pharmaceutical composition further comprises the following components in parts by weight: 10-19 parts of bletilla striata, 4-12 parts of ephedra, 5-15 parts of starwort root, 7-16 parts of cicada shell and 5-12 parts of asarum.
4. The pharmaceutical composition for treating rhinitis according to claim 1, wherein the pharmaceutical composition further comprises the following components in parts by weight: 5-12 parts of bletilla striata, 4-13 parts of asarum, 3-10 parts of ephedra, 10-20 parts of scutellaria baicalensis, 2-7 parts of gardenia, 1-5 parts of dark plum, 3-10 parts of schisandra chinensis and 8-16 parts of rhizoma atractylodis.
5. The pharmaceutical composition for the treatment of rhinitis according to any one of claims 1 to 4, wherein the vegetable oil comprises one or more of sesame oil, tea tree oil, olive oil, rapeseed oil, walnut kernel oil, lemon oil.
6. A process for the manufacture of a pharmaceutical composition for the treatment of rhinitis according to any one of claims 1 to 5, comprising:
soaking the fructus Xanthii, flos Magnoliae, radix astragali, rhizoma Chuanxiong, flos Lonicerae, herba Houttuyniae and flos Chrysanthemi Indici in the vegetable oil for 15-30 hr.
7. The method as claimed in claim 6, wherein the step of soaking further comprises decocting the mixture with slow fire for 0.5-1And (4) hours.
8. The preparation method of claim 7, further comprising filtering the obtained decoction, and adding the borneol, the menthol and the musk into the decoction after the decoction is cooled to below 50 ℃.
9. The method according to claim 8, wherein the decoction is filtered through a 50-100 mesh sieve.
10. The method according to claim 8, wherein the borneol, the menthol and the musk are added into the decoction, and then the mixture is treated by ultrasonic oscillation for 30-50 seconds.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911144429.7A CN110652544A (en) | 2019-11-20 | 2019-11-20 | Pharmaceutical composition for treating rhinitis and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911144429.7A CN110652544A (en) | 2019-11-20 | 2019-11-20 | Pharmaceutical composition for treating rhinitis and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110652544A true CN110652544A (en) | 2020-01-07 |
Family
ID=69043928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911144429.7A Withdrawn CN110652544A (en) | 2019-11-20 | 2019-11-20 | Pharmaceutical composition for treating rhinitis and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110652544A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111603485A (en) * | 2020-07-09 | 2020-09-01 | 长沙善福喜科技有限公司 | Medicine formula for treating rhinitis and preparation method |
| CN117018126A (en) * | 2023-10-09 | 2023-11-10 | 北京辨证堂中医诊所有限公司 | Traditional Chinese medicine formula for treating allergic rhinitis, nasosinusitis, nasal polyp, adenoid hypertrophy and turbinate hypertrophy |
-
2019
- 2019-11-20 CN CN201911144429.7A patent/CN110652544A/en not_active Withdrawn
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111603485A (en) * | 2020-07-09 | 2020-09-01 | 长沙善福喜科技有限公司 | Medicine formula for treating rhinitis and preparation method |
| CN117018126A (en) * | 2023-10-09 | 2023-11-10 | 北京辨证堂中医诊所有限公司 | Traditional Chinese medicine formula for treating allergic rhinitis, nasosinusitis, nasal polyp, adenoid hypertrophy and turbinate hypertrophy |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104127363B (en) | A kind of toothpaste for anti-inflammation, detumescence and sterilization for adults | |
| CN103239662B (en) | Parasite expelling Chinese herbal preparation for animals | |
| CN1251732C (en) | Chinese medicine for treating intrapulmonic infection and SARS | |
| CN101391015A (en) | External traditional Chinese medicine powder for treating recurrent hemorrhoid | |
| CN110652544A (en) | Pharmaceutical composition for treating rhinitis and preparation method thereof | |
| CN114342965A (en) | Traditional Chinese medicine composition for repelling mosquitoes and preparation method thereof | |
| CN107625828A (en) | A kind of health protection tea for auxiliary treatment chronic pharyngitis, preparation method and application | |
| CN104491825B (en) | A kind of Chinese medicine ointment for the treatment of oral ulcer | |
| CN115120690B (en) | Traditional Chinese medicine composition for treating precocious puberty and application thereof | |
| CN103520348A (en) | External traditional Chinese medicine oil for treating haemorrhoids | |
| CN116115689A (en) | Seven-orifice rhinitis-relieving spray and preparation method thereof | |
| CN103845616A (en) | Pharmaceutical composition for eliminating inflammation and disinfecting | |
| CN115381913A (en) | Formula and preparation method of hemorrhoid patch | |
| CN1089845A (en) | A kind of oral medicine and medicine for external use and production method thereof for the treatment of bone disease | |
| CN103690771B (en) | Be used for the treatment of medicine of lamb colibacillosis and preparation method thereof | |
| CN116898937B (en) | Chinese herbal medicine composition and powder for preventing and treating colibacillosis of poultry and application of Chinese herbal medicine composition and powder | |
| CN113509537B (en) | Congjiang Yao bath composition for expelling wind, dispelling cold, sweating and relieving skin and its preparation method and application | |
| CN108452213A (en) | A kind of Chinese medicine for treating rhinitis composition, Chinese medicine preparation and preparation method thereof | |
| CN107233406A (en) | A kind of traditional Chinese medicine for outer use for treating hormone face | |
| CN107648437A (en) | A kind of Chinese medicine for treating rhinitis cream | |
| CN107096017A (en) | Treat dermopathic external medicine composition and its application method | |
| CN106110193A (en) | A kind of external skin ulcer convergence ointment and compound method thereof | |
| CN106540051A (en) | Traditional Chinese medicine composition, powder and ointment for treating rhinitis and preparation method thereof | |
| CN104887808A (en) | Periodontitis treatment traditional Chinese medicine preparation | |
| CN116832122A (en) | Traditional Chinese medicine composition, preparation method, use method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20200107 |